Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-U02 Substudy 02A in anti-PD-1-resistant melanoma
MOH_2020-06-14_009030Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab, quavonlimab, vibostolimab and lenvatinib in melanoma (2 arms), sponsored by Merck & Co. Started Jan 2020; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2020-06-14_009030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-14_009030.